News flow
Regulatory Press Releases
@OrexoABpubl
29 November 2021
Today #orexo looks forward to present at @aktiespararna Stora Aktiedagen. At 2 pm Nikolaj Sørensen CEO will give a… https://t.co/k9oRXZLJUe
@OrexoABpubl
26 November 2021
amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different… https://t.co/uuH4sJEwfT
@OrexoABpubl
26 November 2021
Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will… https://t.co/V0s2CTLGcQ
Europe |
US |
 |
|
|
Lena Wange IR & Corporate Communications Director Switchboard: +46 (0)18 780 88 00 Direct phone: +46 73 064 16 36 Send email: ir@orexo.com Location: Uppsala, Sweden |
Dennis Urbaniak EVP Digital Therapeutics Switchboard: +1 (0)855 982 7658 Direct phone: +1 973 294 3183 Send email: us.media@orexo.com Location: New Jersey, US |
